GlobalData Report

Major acquisitions and venture capital investments signal continued activity despite decline in overall deal value

China, India, and South Korea among the top three countries

The industry reported 102 Venture Capital (VC) deals worth $1.8 billion in October 2022, compared to the last 12-month average…

Venture capital investments decreased by 45.8 per cent in September 2022, compared to September 2021

The majority of the top 20 innovative biopharma companies reported an increase in their revenue in 2021, with an aggregate revenue…

The industry reported 120 Venture Capital (VC) deals worth $2.6 billion in August 2022, compared to the last 12-month average…

The report, ‘Contract Injectable Packaging Trends in the Bio/Pharma Industry,’ has revealed that there was an increase in…

The industry reported 92 Venture Capital (VC) deals worth $2.2 billion in July 2022, compared to the last 12-month average (July…

The industry reported 115 Venture Capital (VC) deals worth $3.7 billion in June 2022, compared to the last 12-month average (June…

The pharma industry reported 78 deals worth $18.6 billion as compared to the last 12-month average (May 2021 to April 2022) of 82…